Patients closer to receiving regenerated tissue major study reveals
11 Dec 2019, 12:20 p.m.
Doctors are closer than ever to using regenerated tissue in treating patients following new breakthroughs in stem cell research published today in Nature Communications.
An international group of researchers led by National Institute for Health Research Professor Paolo De Coppi and Professor Nicola Elvassore at University College London Great Ormond Street Institute of Child Health (UCL GOS ICH) have developed a new gel to grow tissue in the form of organoids so they can be used in human treatment.
Organoids are laboratory grown structures of human stem cells that model the shape and function of tissue such as muscle.
While organoids hold significant potential for use in the replacement and repair of damaged or diseased tissue, the gels currently used to culture human organoids have been unsuitable for use in patients.
However, the researchers led by Professor De Coppi, who is a Consultant Paediatric Surgeon at Great Ormond Street Hospital, have developed an extracellular-matrix (ECM) hydrogel from decellularised piglet intestinal tissue that means organoids could be suitable for use in human treatment.
The new ECM hydrogel provides the same level of support to stem cells in the organoid culture as synthetic gels but meets good practice standards so can be used in a clinical setting.
The study has also advanced knowledge of what is needed to develop a wider range of organoids for use in patients.
Gels used in the development of organoids play an important role in determining the final tissue that is grown. Researchers found their new ECM hydrogel could be used to support cell growth not only in small intestine tissue, but also for liver, stomach and pancreatic tissue.
Their findings mark a step towards clinicians being able to use laboratory developed organoids in clinical settings.
Professor Paolo De Coppi said:
“There is a huge potential for organoids to open up regenerative medicine and advance how we treat complex conditions. Our findings mark a major step towards seeing tissue grown from stem cells being used in clinical settings to treat patients. This could open up the possibility of providing organoid transplants for patients affected by devastating diseases such as short bowel syndrome to improve intestinal function.”
This research was made possible thanks to the generous support of Oak Foundation, Great Ormond Street Hospital Children’s Charity, the Horizon 2020 grant INTENS on the project ‘INtestinal Tissue ENgineering Solution for children with short bowel syndrome’ and the NIHR Great Ormond Street Hospital Biomedical Research Centre.
Research was conducted by a team from UCL GOS ICH, the Francis Crick Institute, ShanghaiTech University, the Royal Netherlands Academy of Arts and Sciences and University Medical Center Utrecht, Princess Maxima Centre for Paediatric Oncology Netherlands and the Telethon Institute of Genetics and Medicine in Italy.
Please note that the image of the Organoid used in this article is the copyright of Professor Paolo De Coppi.
Reducing oxygen levels for children in intensive care will save lives
A new landmark study led from GOSH has found that reducing oxygen levels for critically ill children on mechanical ventilators in intensive care could save lives
GOSH to provide support for AI and Machine Learning as part of new paediatric HealthTech Research Centre
GOSH will support the new Child and Young People’s HealthTech Research Centre (HRC), led by Sheffield Children’s Hospital, as leads for AI and Machine Learning.
Clinical trial results give new hope for children with rare brain tumours
Researchers who are searching for better treatments for an incredibly rare type of brain tumour have published successful results from the latest rounds of clinical trials.
GOSH receives new MHRA authorisation to manufacture viral vectors
GOSH has been granted a Manufacturer's Authorisation Licence for the manufacture of viral vectors, which will accelerate Cell and gene therapies (CGT) clinical trials worldwide and expand the novel treatments that we can offer to our patients.